An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy

Molecular and Cellular Biology

Volumn 34, Issue 4, 2014, Pages 606-618

  Lach Trifilieff, Estelle ^a   Minetti, Giulia C ^a   Sheppard, KellyAnn ^b   Ibebunjo, Chikwendu ^b   Feige, Jerome N ^a,c   Hartmann, Steffen ^a   Brachat, Sophie ^a   Rivet, Helene ^a   Koelbing, Claudia ^a   Morvan, Frederic ^a   Hatakeyama, Shinji ^a   Glass, David J ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; ACTIVIN RECEPTOR 2; BIMAGRUMAB; BYM 338; GLUCOCORTICOID; MONOCLONAL ANTIBODY; MYOSIN HEAVY CHAIN; MYOSTATIN; SMAD2 PROTEIN; SMAD3 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE GROWTH; MUSCLE HYPERTROPHY; MUSCLE MASS; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ACTIVIN RECEPTORS, TYPE II; ACTIVINS; ANIMALS; ANTIBODIES, BLOCKING; ATROPHY; CELL DIFFERENTIATION; HUMANS; HYPERTROPHY; MICE; MUSCLE, SKELETAL; MYOBLASTS, SKELETAL; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN;

EID: 84892954839     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01307-13     Document Type: Article

References (56)

1. Bodine SC. 2013. Disuse-induced muscle wasting. Int. J. Biochem. Cell Biol. 45:2200-2208. http://dx.doi.org/10.1016/j.biocel.2013.06.011.
2. Morley JE. 2012. Sarcopenia in the elderly. Fam. Pract. 29:i44 -i48. http: //dx.doi.org/10.1093/fampra/cmr063.
3. Glass D, Roubenoff R. 2010. Recent advances in the biology and therapy of muscle wasting. Ann. N. Y. Acad. Sci. 1211:25-36. http://dx.doi.org/10 .1111/j.1749-6632.2010.05809.x.
4. Han HQ, Zhou X, Mitch WE, Goldberg AL. 2013. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int. J. Biochem. Cell Biol. 45:2333-2347. http://dx.doi.org/10.1016/j.biocel.2013.05.019.
5. McPherron AC, Lawler AM, Lee SJ. 1997. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387:83-90. http://dx.doi.org/10.1038/387083a0.
6. McPherron AC, Lee SJ. 1997. Double muscling in cattle due to mutations in the myostatin gene. Proc. Natl. Acad. Sci. U. S. A. 94:12457-12461. http://dx.doi.org/10.1073/pnas.94.23.12457.
7. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, Braun T, Tobin JF, Lee SJ. 2004. Myostatin mutation associated with gross muscle hypertrophy in a child. N. Engl. J. Med. 350:2682-2688. http: //dx.doi.org/10.1056/NEJMoa040933.
8. Clop A, Marcq F, Takeda H, Pirottin D, Tordoir X, Bibe B, Bouix J, Caiment F, Elsen JM, Eychenne F, Larzul C, Laville E, Meish F, Milenkovic D, Tobin J, Charlier C, Georges M. 2006. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat. Genet. 38:813-818. http://dx.doi .org/10.1038/ng1810.
9. Mosher DS, Quignon P, Bustamante CD, Sutter NB, Mellersh CS, Parker HG, OstranderEA.2007.Amutationin themyostatingeneincreasesmusclemassand enhances racing performance in heterozygote dogs. PLoS Genet. 3:e79. http://dx .doi.org/10.1371/journal.pgen.0030079.
10. Lee SJ, Reed LA, Davies MV, Girgenrath S, Goad ME, Tomkinson KN, Wright JF, Barker C, Ehrmantraut G, Holmstrom J, Trowell B, Gertz B, Jiang MS, Sebald SM, Matzuk M, Li E, Liang LF, Quattlebaum E, Stotish RL, Wolfman NM. 2005. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci.U.S. A. 102:18117-18122. http://dx .doi.org/10.1073/pnas.0505996102.
11. Lee SJ, Lee YS, Zimmers TA, Soleimani A, Matzuk MM, Tsuchida K, Cohn RD, Barton ER. 2010. Regulation of muscle mass by follistatin and activins. Mol. Endocrinol. 24:1998-2008. http://dx.doi.org/10.1210/me .2010-0127.
12. Trendelenburg AU, Meyer A, Jacobi C, Feige JN, Glass DJ. 2012. TAK-1/p38/nNFkappaB signaling inhibits myoblast differentiation by increasing levels of activin A. Skelet. Muscle 2:3. http://dx.doi.org/10.1186 /2044-5040-2-3.
13. Souza TA, Chen X, Guo Y, Sava P, Zhang J, Hill JJ, Yaworsky PJ, Qiu Y. 2008. Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators. Mol. Endocrinol. 22:2689-2702. http://dx.doi.org/10.1210/me.2008 -0290.
14. McPherron AC, Huynh TV, Lee SJ. 2009. Redundancy of myostatin and growth/differentiation factor 11 function. BMC Dev. Biol. 9:24. http://dx .doi.org/10.1186/1471-213X-9-24.
15. Gamer LW, Cox KA, Small C, Rosen V. 2001. Gdf11 is a negative regulator of chondrogenesis and myogenesis in the developing chick limb. Dev. Biol. 229:407-420. http://dx.doi.org/10.1006/dbio.2000.9981.
16. Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ. 2009. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am. J. Physiol. Cell Physiol. 296:C1258-C1270. http://dx.doi.org/10.1152/ajpcell.00105.2009.
17. Rebbapragada A, Benchabane H, Wrana JL, Celeste AJ, Attisano L. 2003. Myostatin signals through a transforming growth factor {beta}-like signaling pathway to block adipogenesis. Mol. Cell. Biol. 23:7230-7242. http://dx.doi.org/10.1128/MCB.23.20.7230-7242.2003.
18. Lee SJ, McPherron AC. 2001. Regulation of myostatin activity and muscle growth. Proc. Natl. Acad. Sci. U. S. A. 98:9306-9311. http://dx.doi.org/10 .1073/pnas.151270098.
19. Sartori R, Milan G, Patron M, Mammucari C, Blaauw B, Abraham R, Sandri M. 2009. Smad2 and 3 transcription factors control muscle mass in adulthood. Am. J. Physiol. Cell Physiol. 296:C1248-C1257. http://dx.doi .org/10.1152/ajpcell.00104.2009.
20. Glass D. 2010. PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. Curr. Top. Microbiol. Immunol. 346:267-278. http://dx.doi.org /10.1007/82_2010_78.
21. Goncalves MD, Pistilli EE, Balduzzi A, Birnbaum MJ, Lachey J, Khurana TS, Ahima RS. 2010. Akt deficiency attenuates muscle size and function but not the response to ActRIIB inhibition. PLoS One 5:e12707. http://dx.doi.org/10.1371/journal.pone.0012707.
22. Terpos E, Kastritis E, Christoulas D, Gkotzamanidou M, Eleutherakis-Papaiakovou E, Kanellias N, Papatheodorou A, Dimopoulos MA. 2012. Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Ann. Oncol. 23:2681-2686. http://dx.doi.org/10.1093/annonc/mds068.
23. Hoda MA, Munzker J, Ghanim B, Schelch K, Klikovits T, Laszlo V, Sahin E, Bedeir A, Lackner A, Dome B, Setinek U, Filipits M, Eisenbauer M, Kenessey I, Torok S, Garay T, Hegedus B, Catania A, Taghavi S, Klepetko W, Berger W, Grusch M. 2012. Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells. Br. J. Cancer 107:1978-1986. http://dx.doi.org/10.1038/bjc.2012.519.
24. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet WS, Lacey DL, Goldberg AL, Han HQ. 2010. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142:531-543. http://dx.doi.org/10.1016/j .cell.2010.07.011.
25. Whittemore LA, Song K, Li X, Aghajanian J, Davies M, Girgenrath S, Hill JJ, Jalenak M, Kelley P, Knight A, Maylor R, O'Hara D, Pearson A, Quazi A, Ryerson S, Tan XY, Tomkinson KN, Veldman GM, Widom A, Wright JF, Wudyka S, Zhao L, Wolfman NM. 2003. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem. Biophys. Res. Commun. 300:965-971. http: //dx.doi.org/10.1016/S0006-291X(02)02953-4.
26. Bogdanovich S, Perkins KJ, Krag TOB, Whittemore LA, Khurana TS. 2005. Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J. 19:543-549. http://dx.doi.org/10.1096/fj.04-2796com.
27. Attie KM, Borgstein NG, Yang Y, Condon CH, Wilson DM, Pearsall AE, Kumar R, Willins DA, Seehra JS, Sherman ML. 2013. A single ascending-dose study of muscle regulator ace-031 in healthy volunteers. Muscle Nerve 47:416-423. http://dx.doi.org/10.1002/mus.23539.
28. Haenel C, Satzger M, Ducata DD, Ostendorp R, Brocks B. 2005. Characterization of high-affinity antibodies by electrochemiluminescence-based equilibrium titration. Anal. Biochem. 339:182-184. http://dx .doi.org/10.1016/j.ab.2004.12.032.
29. National Research Council. 1995. Guide for the care and use of laboratory animals, 7th ed. National Academies Press, Washington, DC.
30. Ibebunjo C, Chick JM, Kendall T, Eash JK, Li C, Zhang Y, Vickers C, Wu Z, Clarke BA, Shi J, Cruz J, Fournier B, Brachat S, Gutzwiller S, Ma Q, Markovits J, Broome M, Steinkrauss M, Skuba E, Galarneau JR, Gygi SP, Glass DJ. 2013. Genomic and proteomic profiling reveals reduced mitochondrial function and disruption of the neuromuscular junction driving rat sarcopenia. Mol. Cell. Biol. 33:194-212. http://dx.doi.org/10 .1128/MCB.01036-12.
31. Lukjanenko L, Brachat S, Pierrel E, Lach-Trifilieff E, Feige JN. 2013. Genomic profiling reveals that transient adipogenic activation is a hallmark of mouse models of skeletal muscle regeneration. PLoS One 8:e71084. http://dx.doi.org/10.1371/journal.pone.0071084.
32. Grohmann M, Foulstone E, Welsh G, Holly J, Shield J, Crowne E, Stewart C. 2005. Isolation and validation of human prepubertal skeletal muscle cells: maturation and metabolic effects of IGF-I, IGFBP-3 and TNF. J. Physiol. 568:229-242. http://dx.doi.org/10.1113/jphysiol.2005 .093906.
33. Wolfman NM, McPherron AC, Pappano WN, Davies MV, Song K, Tomkinson KN, Wright JF, Zhao L, Sebald SM, Greenspan DS, Lee SJ. 2003. Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc. Natl. Acad. Sci. U. S. A. 100:15842-15846. http://dx .doi.org/10.1073/pnas.2534946100.
34. Li Z, Zhao B, Kim YS, Hu CY, Yang J. 2010. Administration of a mutated myostatin propeptide to neonatal mice significantly enhances skeletal muscle growth. Mol. Reprod. Dev. 77:76-82. http://dx.doi.org/10.1002 /mrd.21111.
35. Wilkes JJ, Lloyd DJ, Gekakis N. 2009. Loss-of-function mutation in myostatin reduces tumor necrosis factor alpha production and protects liver against obesity-induced insulin resistance. Diabetes 58:1133-1143. http://dx.doi.org/10.2337/db08-0245.
36. Anker SD, Clark AL, Kemp M, Salsbury C, Teixeira MM, Hellewell PG, Coats AJS. 1997.Tumornecrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J. Am. Coll. Cardiol. 30:997-1001. http://dx .doi.org/10.1016/S0735-1097(97)00262-3.
37. Fitts RH, Romatowski JG, Peters JR, Paddon-Jones D, Wolfe RR, Ferrando AA. 2007. The deleterious effects of bed rest on human skeletal muscle fibers are exacerbated by hypercortisolemia and ameliorated by dietary supplementation. Am. J. Physiol. Cell Physiol. 293:C313-C320. http://dx.doi.org/10.1152/ajpcell.00573.2006.
38. Ma K, Mallidis C, Bhasin S, Mahabadi V, Artaza J, Gonzalez-Cadavid N, Arias J, Salehian B. 2003. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am. J. Physiol. Endocrinol. Metab. 285:E363-E371. http://dx.doi.org/10.1152 /ajpendo.00487.2002.
39. Gilson H, Schakman O, Combaret L, Lause P, Grobet L, Attaix D, Ketelslegers JM, Thissen JP. 2007. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology 148:452-460. http://dx.doi.org/10.1210/en.2006-0539.
40. Clarke BA, Drujan D, Willis MS, Murphy LO, Corpina RA, Burova E, Rakhilin SV, Stitt TN, Patterson C, Latres E, Glass DJ. 2007. The E3 ligase MuRF1 degrades myosin heavy chain protein in dexamethasonetreated skeletal muscle. Cell Metab. 6:376-385. http://dx.doi.org/10.1016 /j.cmet.2007.09.009.
41. Cohen S, Brault JJ, Gygi SP, Glass DJ, Valenzuela DM, Gartner C, Latres E, Goldberg AL. 2009. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J. Cell Biol. 185:1083-1095. http://dx.doi.org/10.1083/jcb.200901052.
42. Polge C, Heng AE, Jarzaguet M, Ventadour S, Claustre A, Combaret L, Béchet, D, Matondo M, Uttenweiler-Joseph S, Monsarrat B, Attaix D, Taillandier D. 2011. Muscle actin is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1. FASEB J. 25: 3790-3802. http://dx.doi.org/10.1096/fj.11-180968.
43. Elliott B, Renshaw D, Getting S, Mackenzie R. 2012. The central role of myostatin in skeletal muscle and whole body homeostasis. Acta Physiol. 205:324-340. http://dx.doi.org/10.1111/j.1748-1716.2012.02423.x.
44. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, McPherron AC, Wolfman NM, Lee SJ. 2002. Induction of cachexia in mice by systemically administered myostatin. Science 296: 1486-1488. http://dx.doi.org/10.1126/science.1069525.
45. Lakshman KM, Bhasin S, Corcoran C, Collins-Racie LA, Tchistiakova L, Forlow SB, St Ledger K, Burczynski ME, Dorner AJ, Lavallie ER. 2009. Measurement of myostatin concentrations in human serum: circulating concentrations in young and older men and effects of testosterone administration. Mol. Cell. Endocrinol. 302:26-32. http://dx.doi.org/10 .1016/j.mce.2008.12.019.
46. Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, Flanigan KM, Pestronk A, Tawil R, Wolfe GI, Eagle M, Florence JM, King WM, Pandya S, Straub V, Juneau P, Meyers K, Csimma C, Araujo T, Allen R, Parsons SA, Wozney JM, LaVallie ER, Mendell JR. 2008. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann. Neurol. 63:561-571. http://dx.doi.org/10.1002/ana.21338.
47. Welle S, Bhatt K, Pinkert CA, Tawil R, Thornton CA. 2007. Muscle growth after postdevelopmental myostatin gene knockout. Am. J. Physiol. Endocrinol. Metab. 292:E985-E991. http://dx.doi.org/10.1152/ajpendo .00531.2006.
48. Lee SJ. 2007. Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS One 2:e789. http://dx.doi.org/10.1371/journal .pone.0000789.
49. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD. 2001. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 3:1014-1019. http://dx.doi.org/10.1038/ncb1101-1014.
50. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD, Glass DJ. 2001. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3:1009-1013. http://dx.doi.org/10.1038/ncb1101 -1009.
51. Pereira C, Murphy K, Jeschke M, Herndon DN. 2005. Post burn muscle wasting and the effects of treatments. Int. J. Biochem. Cell Biol. 37:1948-1961. http://dx.doi.org/10.1016/j.biocel.2005.05.009.
52. Deutschman CS, Konstantinides FN, Raup S, Cerra FB. 1987. Physiological and metabolic response to isolated closed-head injury. J. Neurosurg. 66:388-395. http://dx.doi.org/10.3171/jns.1987.66.3.0388.
53. Amthor H, Macharia R, Navarrete R, Schuelke M, Brown SC, Otto A, Voit T, Muntoni F, Vrbóva G, Partridge T, Zammit P, Bunger L, Patel K. 2007. Lack of myostatin results in excessive muscle growth but impaired force generation. Proc. Natl. Acad. Sci. U. S. A. 104:1835-1840. http://dx.doi.org/10.1073/pnas.0604893104.
54. Busquets S, Toledo M, Orpi M, Massa D, Porta M, Capdevila E, Padilla N, Frailis V, Lopez-Soriano FJ, Han HQ, Argiles JM. 2012. Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J. Cachexia Sarcopenia Muscle 3:37-43. http://dx.doi.org/10.1007 /s13539-011-0049-z.
55. Akpan I, Goncalves MD, Dhir R, Yin X, Pistilli EE, Bogdanovich S, Khurana TS, Ucran J, Lachey J, Ahima RS. 2009. The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity. Int. J. Obes. (Lond.) 33:1265-1273. http://dx.doi.org/10.1038/ijo.2009.162.
56. Fournier B, Murray B, Gutzwiller S, Marcaletti S, Marcellin D, Bergling S, Brachat S, Persohn E, Pierrel E, Bombard F, Hatakeyama S, Trendelenburg AU, Morvan F, Richardson B, Glass DJ, Lach-Trifilieff E, Feige JN. 2012. Blockade of the activin receptor IIB activates functional brown adipogenesis and thermogenesis by inducing mitochondrial oxidative metabolism. Mol. Cell. Biol. 32:2871-2879. http://dx.doi.org/10.1128 /MCB.06575-11.